
-
Cara Therapeutics NasdaqCM:CARA Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Location: 400 Atlantic Street, Stamford, CT, 06901, United States | Website: https://www.caratherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
30.88M
Cash
37.9M
Avg Qtr Burn
-15.23M
Short % of Float
1.70%
Insider Ownership
13.07%
Institutional Own.
24.17%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Korsuva IV (CR845 IV) Details Pruritus with chronic kidney disease , Kidney disease | Approved Quarterly sales | |
Oral Korsuva (difelikefalin) (CR845) Details Chronic liver disease, Liver disease, Chronic pruritus, Hemophilia, Blood disorder | Failed Discontinued | |
Oral Korsuva (difelikefalin) (CR845) Details Chronic pruritus, Pruritus associated with notalgia paresthetica | Failed Discontinued | |
Oral Korsuva (difelikefalin)(CR845) Details Inflammatory disease, Skin disease/disorder, Atopic dermatitis, Atopic pruritus | Failed Discontinued | |
Oral Korsuva (difelikefalin) (CR845) Details Pruritus with chronic kidney disease , Chronic kidney disease | Failed Discontinued |